KD-287 fulfilled the non-inferiority criteria for seroconversion rate ( SCR ) and geometric mean titer ( GMT ) of the neutralizing antibody , which were the primary endpoints , at 4weeks after the third vaccination ( 95 % CI : -1.00 , 3.10 for the SCR difference and 10.8 , 17.6 for the GMT ratio ) .